Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• BareschinoMASchettinoCRossiATreatment of advanced non small cell lung cancerJ Thorac Dis20113212213322263075
   PubMedGoogle Scholar
• KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet200837296521809181819027483
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• IaconoDChiariRMetroGFuture options for ALK-positive non-small cell lung cancerLung Cancer201587321121925601484
   PubMed Web of Science ®Google Scholar
• SocinskiMAEvansTGettingerSTreatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20131435 Supple341Se368S23649446
   PubMed Web of Science ®Google Scholar
• AsahinaHSekineIHorinouchiHRetrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancerClin Lung Cancer2012131394321890422
   PubMed Web of Science ®Google Scholar
• ChenYMShihJFFanWCThird-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance statusJ Chin Med Assoc201174520921421550007
   PubMed Web of Science ®Google Scholar
• StinchcombeTEThe use of EGFR tyrosine kinase inhibitors in EGFR wild-type non-small-cell lung cancerCurr Treat Options Oncol20161741826961971
   PubMed Web of Science ®Google Scholar
• LaukoAThapaBVenurVAAhluwaliaMSManagement of brain metastases in the new era of checkpoint inhibitionCurr Neurol Neurosci Rep201818107030121715
   PubMed Web of Science ®Google Scholar
• LeeCKManJLordSCheckpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysisJ Thorac Oncol201712240340727765535
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immuno-therapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• RibasAAdaptive immune resistance: how cancer protects from immune attackCancer Discov20155991591926272491
   PubMed Web of Science ®Google Scholar
• PuXWuLSuDMaoWFangBImmunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistanceBMC Cancer2018181108230409126
   PubMedGoogle Scholar
• RibasAWolchokJDCancer immunotherapy using checkpoint blockadeScience201835963821350135529567705
   PubMed Web of Science ®Google Scholar
• GandhiLRodríguez-AbreuDGadgeelSKEYNOTE-189 InvestigatorsPembrolizumab plus chemotherapy in metastatic non-small-cell lung cancerN Engl J Med2018378222078209229658856
   PubMed Web of Science ®Google Scholar
• VokesEEReadyNFelipENivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastasesAnn Oncol201829495996529408986
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med20153731627163926412456
   PubMed Web of Science ®Google Scholar
• GovindanRSzczesnaAAhnMJPhase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancerJ Clin Oncol201735303449345728854067
   PubMed Web of Science ®Google Scholar
• MoherDCookDJEastwoodSOlkinIRennieDStroupDFImproving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analysesLancet199935491931896190010584742
   PubMed Web of Science ®Google Scholar
• CheyneWWAn address on acute abdominal symptoms: delivered before the Walthamstow division of the metropolitan counties branch of the British medical associationBr Med J1905123201313131620762161
   PubMedGoogle Scholar
• ZintzarasEIoannidisJPHeterogeneity testing in meta-analysis of genome searchesGenet Epidemiol200528212313715593093
   PubMed Web of Science ®Google Scholar
• DersimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMSmithGDSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• BrahmerJReckampKLBaasPNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerN Engl J Med201537312313526028407
   PubMed Web of Science ®Google Scholar
• LynchTJBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyJ Clin Oncol201230172046205422547592
   PubMed Web of Science ®Google Scholar
• RittmeyerABarlesiFWaterkampDAtezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet20173891006625526527979383
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• ReckMRodríguez-AbreuDRobinsonAGPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerN Engl J Med2016375191823183327718847
   PubMed Web of Science ®Google Scholar
• HellmannMDCiuleanuTEPluzanskiANivolumab plus ipilimumab in lung cancer with a high tumor mutational burdenN Engl J Med2018378222093210429658845
   PubMed Web of Science ®Google Scholar
• SocinskiMAJotteRMCappuzzoFIMpower150 Study GroupAtezolizumab for first-line treatment of metastatic nonsquamous NSCLCN Engl J Med2018378242288230129863955
   PubMed Web of Science ®Google Scholar
• JonesCMBrunelliACallisterMEFranksKNMultimodality treatment of advanced non-small cell lung cancer: where are we with the evidence?Curr Surg Rep201862529456881
   PubMed Web of Science ®Google Scholar
• AntoniaSJVillegasADanielDDurvalumab after chemoradiotherapy in stage III non-small-cell lung cancerN Engl J Med2017377201919192928885881
   PubMed Web of Science ®Google Scholar
• RovielloGAndreFVenturiniSResponse rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studiesEur J Cancer20178625726529055841
   PubMed Web of Science ®Google Scholar